ArticleFrontiers in immunology2022
Clinical and immunological characteristics of
Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Management and Immunotherapy for Fungal Allergy: Clinical Practice and Unmet Needs.Clinical reviews in allergy & immunology · 2026Review
- Relapsing allergic bronchopulmonary aspergillosis as a trigger for Kounis syndrome: a case report.Frontiers in cardiovascular medicine · 2026Article
- Eosinophil-Derived Neurotoxin: A Potential Biomarker for Allergic Bronchopulmonary Aspergillosis.Journal of asthma and allergy · 2026Article
- Asthma and Allergic Bronchopulmonary Aspergillosis: Understanding, Insights, and State-of-the-Art.Journal of inflammation research · 2026Review
- Review
- Emergence, function, and therapeutic strategies to target the PD-1/PD-L1 immune checkpoint during pathogenic fungal infections.Virulence · 2025Review
- The management of type 2 inflammatory respiratory diseases: a Chinese expert consensus [2024].Journal of thoracic disease · 2025Review
- High level of initial Aspergillus fumigatus-specific IgE links increased risk of exacerbation in allergic bronchopulmonary aspergillosis patients.Respiratory research · 2025Article
- Development and validation of a clinical prediction model forFrontiers in medicine · 2025Article
- Rethinking Aspergillosis in the Era of Microbiota and Mycobiota.Mycopathologia · 2024Review
- Th2-skewed peripheral T-helper cells drive B-cells in allergic bronchopulmonary aspergillosis.The European respiratory journal · 2024Article
- Clinical Relevance of Elevated Serum Carcinoembryonic Antigen in Allergic Bronchopulmonary Aspergillosis/Mycosis: A Multicenter Retrospective Study.Journal of asthma and allergy · 2024Article
- Management of comorbidities in difficult and severe asthma.Breathe (Sheffield, England) · 2023Review
- Aspergillus-Specific IgG Antibodies are Associated With Fungal-Related Complications and Chronic Lung Allograft Dysfunction After Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
- Distribution ofTherapeutic advances in infectious diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objective: We aimed to investigate the clinical and immunological characteristics of Methods: A total of 64 ABPA and 57 A Results: The eosinophils in blood, induced sputum, and FeNO were significantly higher in ABPA patients compared to that in Conclusion: Our findings suggest the distinct humoral and cell immunological responses in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.